Monarch Partners Asset Management’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $1.7M | Sell |
613,837
-187,422
| -23% | -$519K | 0.5% | 99 |
|
|
2022
Q3 | $2.05M | Hold |
801,259
| – | – | 0.62% | 80 |
|
|
2022
Q2 | $2.89M | Buy |
801,259
+308,057
| +62% | +$1.11M | 0.81% | 49 |
|
|
2022
Q1 | $3.06M | Hold |
493,202
| – | – | 0.68% | 61 |
|
|
2021
Q4 | $3.48M | Buy |
493,202
+163,119
| +49% | +$1.15M | 0.71% | 57 |
|
|
2021
Q3 | $2.3M | Sell |
330,083
-14,156
| -4% | -$98.8K | 0.34% | 104 |
|
|
2021
Q2 | $2.87M | Buy |
+344,239
| New | +$2.87M | 0.41% | 88 |
|
|
2020
Q1 | – | Sell |
-123,470
| Closed | -$377K | – | 170 |
|
|
2019
Q4 | $377K | Hold |
123,470
| – | – | 0.08% | 162 |
|
|
2019
Q3 | $380K | Buy |
123,470
+14,630
| +13% | +$45K | 0.06% | 160 |
|
|
2019
Q2 | $218K | Hold |
108,840
| – | – | 0.03% | 165 |
|
|
2019
Q1 | $469K | Buy |
+108,840
| New | +$469K | 0.07% | 157 |
|